“Gene Therapy”

16 result(s)
Drug Pipeline
What's Next for Hemophilia Treatments?
What's Next for Hemophilia Therapy and New Treatment Options? More
Briefing
Health Equity
Marketplace Trends Shape Specialty Landscape
... More
Briefing
Specialty
Three Major Challenges Facing Gene Therapy
The Top Challenges Facing Gene Therapy Today More
Briefing
Drug Pipeline
A Q2 2022 Look at Projected Gene Therapies and Approval Timelines
A Q2 2022 Look at Projected Gene Therapies and FDA Approval Timelines More
Briefing
Drug Pipeline
Treatment Options Expand in Robust Gene Therapy Pipeline
New Gene Therapies for Sickle Cell Disease, Hemophilia on the Horizon More
Briefing
Drug Pipeline
Expanding Therapies, Indications and Implications for Payors
2022 Marketplace Outlook: Expanding Therapies, Indications and Implications for Payors More
Briefing
Drug Pipeline
Breakthrough Therapies and New Biologics Feature in the Gene Therapy Pipeline
Breakthrough Therapies and New Biologics Feature in the Gene Therapy Pipeline More
Briefing
Health Equity
Great Strides in Managing Sickle Cell Disease
Great strides are being made in managing sickle cell disease to address patient pain and payor costs. More
Commentary
Drug Pipeline
Gene Therapies in the Pipeline Highlight a Variety of Conditions and Anticipated Treatments
The gene therapy pipeline report highlights what payors can expect for a variety of conditions. More
Briefing
Near-Term Outlook for Projected Gene Therapies and Their Approval Timelines | Payor Solutions
Drug Pipeline
Near-Term Outlook for Projected Gene Therapies and Their Approval Timelines
Projected Approvals of Pipeline Gene Therapies Expected to Treat Conditions with Few Options More
Briefing